173 related articles for article (PubMed ID: 11388646)
21. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.
Kato S; Luyckx VA; Ots M; Lee KW; Ziai F; Troy JL; Brenner BM; MacKenzie HS
Kidney Int; 1999 Sep; 56(3):1037-48. PubMed ID: 10469372
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
Malmqvist K; Kahan T; Dahl M
Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
[TBL] [Abstract][Full Text] [Related]
23. Chronic treatment with angiotensin II type 1 receptor antagonist suppresses glomerular activator protein-1 activity in salt-sensitive hypertensive rats.
Otsuka F; Ogura T; Yamauchi T; Sato M; Kataoka H; Kageyama J; Makino H
Kidney Blood Press Res; 2000; 23(1):35-41. PubMed ID: 10567852
[TBL] [Abstract][Full Text] [Related]
24. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
Ziai F; Ots M; Provoost AP; Troy JL; Rennke HG; Brenner BM; Mackenzie HS
Kidney Int Suppl; 1996 Dec; 57():S132-6. PubMed ID: 8941934
[TBL] [Abstract][Full Text] [Related]
25. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
26. Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats.
Fredersdorf S; Weil J; Ulucan C; Birner C; Büttner R; Schubert T; Böger CA; Debl K; Muders F; Riegger GA; Luchner A
Naunyn Schmiedebergs Arch Pharmacol; 2007 Apr; 375(2):95-103. PubMed ID: 17333128
[TBL] [Abstract][Full Text] [Related]
27. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
28. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
Iimura O; Kusano E; Tanba K; Yanagiba S; Amemiya M; Ando Y; Honma S; Muto S; Asano Y
Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
[TBL] [Abstract][Full Text] [Related]
29. Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.
Zhou A; Yu L; Li J; Zhang J; Wang H
Hypertens Res; 2000 Jul; 23(4):391-7. PubMed ID: 10912779
[TBL] [Abstract][Full Text] [Related]
30. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
Sebeková K; Lill M; Boor P; Heidland A; Amann K
Am J Nephrol; 2009; 29(3):164-70. PubMed ID: 18753741
[TBL] [Abstract][Full Text] [Related]
31. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
Kincaid-Smith P; Fairley K; Packham D
Nephrol Dial Transplant; 2002 Apr; 17(4):597-601. PubMed ID: 11917051
[TBL] [Abstract][Full Text] [Related]
32. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
33. Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
Hollenberg NK
J Hypertens Suppl; 1997 Dec; 15(7):S7-13. PubMed ID: 9532515
[TBL] [Abstract][Full Text] [Related]
34. The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice.
Peten EP; Striker LJ; Fogo A; Ichikawa I; Patel A; Striker GE
Mol Med; 1994 Nov; 1(1):104-15. PubMed ID: 8790606
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist.
Okamura M; Konishi Y; Nishimura M; Umetani N; Iwai J; Negoro N; Inoue T; Takeda T; Kanayama Y
Blood Press Suppl; 1994; 5():75-8. PubMed ID: 7889207
[TBL] [Abstract][Full Text] [Related]
36. Candesartan cilexetil: an angiotensin II-receptor blocker.
See S; Stirling AL
Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
[TBL] [Abstract][Full Text] [Related]
37. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Kincaid-Smith P; Fairley KF; Packham D
Nephrol Dial Transplant; 2004 Sep; 19(9):2272-4. PubMed ID: 15252156
[TBL] [Abstract][Full Text] [Related]
38. Chronically increased intrarenal angiotensin II causes nephropathy in an animal model of type 2 diabetes.
Sharma R; Sharma M; Reddy S; Savin VJ; Nagaria AM; Wiegmann TB
Front Biosci; 2006 Jan; 11():968-76. PubMed ID: 16146787
[TBL] [Abstract][Full Text] [Related]
39. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
40. Candesartan prevents the progression of mesangioproliferative nephritis in rats.
Nakamura T; Obata J; Onizuka M; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
Kidney Int Suppl; 1997 Dec; 63():S226-8. PubMed ID: 9407466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
